The science
Ipamorelin research: mechanism, the body-composition evidence, and the comparisons that matter
Every quantitative claim is attributed to a study. Selectivity is the through-line.
Start here
Ipamorelin works by flipping one switch: a receptor on the pituitary gland called GHS-R1a, the same one the hunger hormone ghrelin uses [1]. Flipping it releases a pulse of growth hormone. What makes ipamorelin unusual is what it does not do — it leaves cortisol and prolactin alone, even at high doses [1]. For body composition, the studies show two things at once. Growth hormone signaling builds lean tissue and bone, and in rats ipamorelin grew bone even without a rise in IGF-1, the usual messenger [4]. But the same receptor also sits in appetite circuits, so ipamorelin can raise hunger and fat in animals through a separate, growth-hormone-independent route [7][8]. The sections below walk through the mechanism, the body-composition data, the pharmacokinetics, and how ipamorelin compares with the GHRH-type peptides it is often paired with.
Mechanism: a selective ghrelin-receptor agonist
Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs — the cells that make growth hormone — triggering a discrete pulse of release [1]. Mechanistically, receptor activation runs through a Gq/phospholipase-C pathway that raises intracellular calcium and drives growth-hormone secretion. The defining experiment came in 1998: in primary rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released growth hormone potently (swine ED50 of 2.3 nmol/kg, comparable to GHRP-6 at 3.9 nmol/kg) yet did not raise ACTH or cortisol above the level seen with GHRH even at doses more than 200-fold above its growth-hormone ED50 [1]. It releases growth hormone by a mechanism distinct from GHRH, which is precisely why it is combined with GHRH analogs — the two pathways are complementary rather than redundant.
The body-composition evidence
The clearest skeletal result is the 1999 bone study: subcutaneous ipamorelin at 18, 90, and 450 μg/day (divided three times daily for 15 days) raised the longitudinal bone-growth rate of adult female rats from 42 μm/day on vehicle to 44, 50, and 52 μm/day — a clean dose-response — with no measurable change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The absence of an IGF-1 change is the headline: it indicates a partly local, growth-hormone-pulse-driven skeletal effect rather than a systemic IGF-1 mechanism. On the fat and appetite side, two weeks of twice-daily subcutaneous ipamorelin raised body weight by roughly 15% in both growth-hormone-deficient (lit/lit) and growth-hormone-intact mice, with elevated fat-pad weights and serum leptin in both genotypes [7]. Because the effect appeared even in growth-hormone-deficient animals, part of ipamorelin's influence on adiposity is growth-hormone-independent. The mechanistic basis for the appetite half is well established: acute central administration of ghrelin and growth-hormone secretagogues activates hypothalamic appetite centers and induces feeding in rats [8]. A separate line of work on the growth-hormone axis and nitrogen balance provides the protein-anabolism rationale often attached to these peptides, though it is not an ipamorelin-specific efficacy demonstration [9]. Taken together: a real lean-and-bone signal, a real appetite-and-fat signal, and a body-composition outcome that depends on which one dominates in a given protocol.
Pharmacokinetics and metabolic context
In healthy male volunteers, population PK/PD modeling across five intravenous dose levels (4.21 to 140.45 nmol/kg over 15 minutes) showed dose-proportional kinetics with a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg; the growth-hormone response peaked as a single discrete pulse about 40 minutes (0.67 h) after dosing [2]. In rats, ipamorelin showed roughly 5-fold lower plasma clearance than GHRP-6, with 60 to 80% of the dose recovered intact in bile and urine and an intranasal bioavailability of about 20% — greater metabolic stability than GHRP-6, but only modest nasal absorption [11]. Metabolic state matters: in streptozotocin-diabetic mice, intravenous ipamorelin produced markedly greater growth-hormone hypersecretion (150 ± 35 µg/L) than in non-diabetic controls (62 ± 11 µg/L), alongside hepatic growth-hormone-receptor resistance and suppressed IGF-1 [10]. And ipamorelin's growth-hormone release survives glucocorticoid suppression: methylprednisolone (5.0 mg/kg/day for 8 days) did not blunt the acute growth-hormone response in rats, and the combination raised IGF-1 and improved body-weight recovery versus steroid alone [12].
What is ipamorelin peptide
Ipamorelin is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — derived from the earlier peptide GHRP-1 by removing its central Ala-Trp dipeptide [1]. The non-natural alpha-aminoisobutyric acid (Aib) at position 1 and the D-form amino acids give it resistance to the enzymes that would otherwise chew up a normal peptide. It is not an endogenous human molecule; it mimics the action of ghrelin at the GHS-R1a receptor. Its defining property is selectivity — growth hormone up, cortisol and prolactin flat — which is what distinguishes "ipamorelin peptide" from the broader, less selective GHRP class [1]. Its medicinal-chemistry lineage is well documented: a peptidomimetic series derived from the ipamorelin scaffold reached comparable in-vivo potency (ED50 ~2 nmol/kg IV in swine) while attaining roughly 10% oral bioavailability in dogs, showing the pharmacophore could be engineered toward orally active secretagogues [13].
What is cjc 1295 ipamorelin
"CJC-1295 ipamorelin" refers to pairing ipamorelin with CJC-1295, a long-acting GHRH analog. The rationale is mechanistic: ipamorelin acts on the ghrelin receptor (GHS-R1a), while CJC-1295 acts on the separate GHRH receptor [1]. Because the two pathways are distinct and complementary, co-administration is intended to produce a larger, more physiological growth-hormone pulse than either alone. The crucial caveat is evidentiary: the combination has never been tested in a controlled human trial for any outcome. Its support comes entirely from the separate single-agent pharmacology of each peptide, not from combination data — a point the dosage and effects pages return to.
Ipamorelin cjc-1295
What direct evidence exists for ipamorelin cjc-1295 as a pair is preclinical and recent. A 2026 narrative review from the USC Keck School of Medicine reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model, while explicitly noting that the evidence is limited to animal studies [16]. That is the strongest combination-specific signal in the literature, and it is a single animal finding inside a review, not a human trial. For body composition specifically, no controlled human study has measured what the pair does to lean mass or fat — the combination's reputation rests on extrapolation from each component's mechanism, not on outcome data.
Does cjc-1295 ipamorelin work
It depends entirely on what "work" means. Pharmacologically, each component does what it is designed to do — ipamorelin releases growth hormone selectively [1] and CJC-1295 extends GHRH signaling — and in one murine model the pair improved muscle tetanic tension under glucocorticoid stress [16]. Clinically, there is no controlled human trial of the combination for body composition, recovery, anti-aging, or any other outcome [16]. So the defensible answer is: the mechanism is real and animal data are suggestive, but no human outcome trial has demonstrated that the combination "works" for the goals people typically pursue with it.
Ipamorelin vs sermorelin
Ipamorelin and sermorelin raise growth hormone through different receptors. Sermorelin is a GHRH analog — it acts on the GHRH receptor and was an approved drug formulation, used historically in pediatric growth assessment. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist that was never approved and acts on a completely separate pathway [1][3]. Functionally, this is why the two are often paired rather than chosen between: a GHRH analog like sermorelin and a ghrelin-receptor agonist like ipamorelin hit complementary mechanisms. Ipamorelin's distinguishing feature within any such comparison is selectivity — it raises growth hormone without the cortisol and prolactin elevation seen with less selective ghrelin-receptor peptides [1].
Ipamorelin vs tesamorelin
Tesamorelin is a GHRH analog with an approved human indication (HIV-associated lipodystrophy) and a body of human trial data behind that use. Ipamorelin is a ghrelin-receptor agonist with no approved indication and one failed Phase 2 trial [3]. The mechanistic contrast is the same as with sermorelin — GHRH-receptor versus ghrelin-receptor — but the evidentiary contrast is sharper: tesamorelin has controlled human efficacy data for its approved use, whereas ipamorelin's human record is a single negative ileus trial and an acute pharmacokinetic study [3][2]. For body composition, that means tesamorelin's visceral-fat effect rests on human data, while ipamorelin's body-composition profile rests on rodent studies and mechanism [4][7].